Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ryosuke Koretomo"'
Autor:
Tadao Akizawa, Masaomi Nangaku, Takuhiro Yamaguchi, Ryosuke Koretomo, Kazuo Maeda, Yuya Miyazawa, Hideki Hirakata
Publikováno v:
Kidney Diseases, Pp 1-9 (2021)
Introduction: Enarodustat (JTZ-951) is a new oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). We conducted a phase 3 study to compare the efficacy and safety of enarodustat with d
Externí odkaz:
https://doaj.org/article/756ce7cdeb974b31b371c3e53f66b5da
Autor:
Takuhiro Yamaguchi, Ryosuke Koretomo, Hideki Hirakata, Yuya Miyazawa, Tadao Akizawa, Kazuo Maeda, Masaomi Nangaku
Publikováno v:
Kidney International Reports
Introduction Enarodustat (JTZ-951) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that might be a new therapeutic approach for managing anemia in patients with chronic kidney disease (CKD). We evaluated the efficacy (noninferiority
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf2fbab8b8a4b4b12ca0fcfa4ba195d9
https://doi.org/10.1016/j.ekir.2021.04.037
https://doi.org/10.1016/j.ekir.2021.04.037
Autor:
Masaomi Nangaku, Tadao Akizawa, Ryosuke Koretomo, Yuya Miyazawa, Hideki Hirakata, Kazuo Maeda, Takuhiro Yamaguchi
Publikováno v:
Kidney Diseases, Pp 1-9 (2021)
Kidney Dis (Basel)
Kidney Dis (Basel)
Introduction: Enarodustat (JTZ-951) is a new oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). We conducted a phase 3 study to compare the efficacy and safety of enarodustat with d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbf2f015b859984f942d02ce89289f4b
https://doi.org/10.1159/000517053
https://doi.org/10.1159/000517053
Autor:
Tadao Akizawa, Ryosuke Koretomo, Masaomi Nangaku, Takuhiro Yamaguchi, Kazuo Maeda, Osamu Yamada, Hideki Hirakata
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 26(2)
Enarodustat (JTZ-951) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed for treating anemia in chronic kidney disease. Two open-label, uncontrolled phase 3 studies evaluated the 52-week safety and efficacy of enarodustat in J
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7238535cfbf8b5a6ba9dba638f7dc79a
https://pubmed.ncbi.nlm.nih.gov/34390314
https://pubmed.ncbi.nlm.nih.gov/34390314
Autor:
Maekawa Michihide, Ryosuke Koretomo, Sudhakar M. Pai, Seiji Enya, Barbara Gerhardt, Tomohiro Ishikawa, Hiromasa Tanaka, Hiroyuki Yamada, Jeffrey Connaire
Publikováno v:
Clinical Pharmacology in Drug Development. 9:728-741
The mass balance, pharmacokinetics, and biotransformation of JTZ-951 (enarodustat), a novel hypoxia-inducible factor prolyl hydroxylase inhibitor, were characterized in patients (N = 6) with end-stage renal disease on hemodialysis. Following a 10-mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0083e55fecc7c89c32991b87022fd0b
https://doi.org/10.1002/cpdd.752
https://doi.org/10.1002/cpdd.752
Autor:
Takuhiro Yamaguchi, Ryosuke Koretomo, Hideki Hirakata, Yuya Miyazawa, Kazuo Maeda, Masaomi Nangaku, Tadao Akizawa, Masanobu Arai
Publikováno v:
Nephron. 143:77-85
Background: Enarodustat (JTZ-951) is an orally available hypoxia-inducible factor prolyl hydroxylase inhibitor that increases endogenous erythropoietin levels in the treatment of anemia associated with chronic kidney disease (CKD). Objective: A phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d17a0fe550198dea0f1470690b935b53
https://doi.org/10.1159/000500487
https://doi.org/10.1159/000500487
Autor:
Qingtao Mike Huang, Ryosuke Koretomo, Rui Zhuo, Robert B Kleiman, Hiroyuki Yamada, Sudhakar M. Pai
Publikováno v:
Clinical pharmacology in drug developmentReferences. 10(8)
This study evaluated the effect of enarodustat on cardiac repolarization in healthy subjects. Enarodustat (20 and 150 mg [supratherapeutic dose]), placebo, and moxifloxacin (positive control, 400 mg) were administered orally to males and females (N =
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b8f84e807d584da0b15829a276f59c1
https://pubmed.ncbi.nlm.nih.gov/34159762
https://pubmed.ncbi.nlm.nih.gov/34159762
Autor:
Sudhakar M, Pai, Jeffrey, Connaire, Hiroyuki, Yamada, Seiji, Enya, Barbara, Gerhardt, Michihide, Maekawa, Hiromasa, Tanaka, Ryosuke, Koretomo, Tomohiro, Ishikawa
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(6)
The mass balance, pharmacokinetics, and biotransformation of JTZ-951 (enarodustat), a novel hypoxia-inducible factor prolyl hydroxylase inhibitor, were characterized in patients (N = 6) with end-stage renal disease on hemodialysis. Following a 10-mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2d927ba050536095f63818da98d196d0
https://pubmed.ncbi.nlm.nih.gov/31876104
https://pubmed.ncbi.nlm.nih.gov/31876104
Autor:
Naoko Kanagawa, Ryosuke Koretomo, Naoki Okada, Takuya Fujita, Shinsaku Nakagawa, Fuminori Sakurai, Hiroyuki Mizuguchi, Sayaka Murakami, Akira Yamamoto
Publikováno v:
Virology. 374:411-420
Adenoviral vector (Ad)-mediated gene transfer is an attractive method for manipulating the immunostimulatory properties of dendritic cells (DCs) for cancer immunotherapy. DCs treated with Ad have phenotype alterations (maturation) that facilitate T c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1af87ae4f67efaa15e2b3e24778f0acc
https://doi.org/10.1016/j.virol.2007.12.043
https://doi.org/10.1016/j.virol.2007.12.043